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Abstract The aim of this study was to analyze relationships
between receptor activator of nuclear factor kappa-B
(RANKL), sclerostin and their gene polymorphisms with ra-
diological progression in patients with early rheumatoid ar-
thritis (RA). Patients with early RA (n = 407, symptomatic
<1 year) (ARA criteria) examined radiologically at inclusion
and after 24 months were consecutively included. Disease
activity score and C-reactive protein were regularly recorded.
Sclerostin, RANKL, and anti-CCP2 antibodies were analyzed
in plasma at baseline using ELISAs. Data on gene polymor-
phism for sclerostin and RANKL were extracted from
Immunochip analysis. Sex- and age-matched controls
(n = 71) were identified from the Medical Biobank of
Northern Sweden. The concentration of RANKL was signif-
icantly higher in patients compared with controls, median
(IQR) 0.56 (0.9) nmol/L and 0.20 (0.25) nmol/L (p < 0.001),
and in anti-CCP2-positive patients compared with sero-
negative individuals. Sclerostin was significantly increased
in female patients 0.59 (0.47–0.65) ng/mL compared with
female controls 0.49 (0.4–0.65) ng/mL (p < 0.02). RANKL
concentration was related to the Larsen score at baseline
(p < 0.01), after 24 months (p < 0.001), and to radiological
progression at 24 months (p < 0.001). Positivity of RANKL
and anti-CCP2 yielded significant risk for progression with
negativity for both as reference. No single nucleotide poly-
morphism encoding TNFSF11 or SOST was associated with
increased concentrations of the factors. The concentration of
RANKL was related to the Larsen score at baseline, at
24 months, and radiological progression at 24 months partic-
ularly in anti-CCP2-positive patients, while the concentration
of sclerostin was unrelated to radiological findings.
Keywords Early rheumatoid arthritis . Radiological
progression . Receptor activator of nuclear factor kappa-B
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by joint inflammation that eventually leads to
the destruction of cartilage and bone (1). The destructive pro-
cess is related to the presence of autoantibodies, genetic poly-
morphism involving proteins in theWingless (Wnt)-β-catenin
pathway, and markers of inflammation, cartilage and bone
metabolism (2, 3).
Receptor activator of NF kappa B Ligand (RANKL) is a
member of the tumor necrosis factor (TNF) family of cyto-
kines and is coded for by the tumor necrosis factor ligand
superfamily member 11 (TNFSF11) gene. The protein plays
a central role in osteoclast differentiation and activation and
the RANKL/osteoprotegerin pathway (RANKL/OPG) is
strongly upregulated by pro-inflammatory cytokines (4).
This is an important pathway for inflammatory bone loss in
patients with RA (5). RANKL is not only expressed in osteo-
cytes and osteoblasts but also in synovial cells, activated T
cells, B cells, and natural killer cells (4). Synovial cells ex-
pressing RANKL are responsible for the formation of osteo-
clasts and bone loss in an experimental model of RA directly
linking the immune system to bone (6). Furthermore, bone
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erosions can be retarded in RA patients by clinical blockage of
RANKL (7).
Sclerostin is an osteocyte-specific protein that is a product
of the SOST gene and is a potent suppressor of bone formation
(8). Sclerostin inhibits the Wnt-signaling pathway, thereby
blocking osteoblast formation and inhibiting the production
of bone (9). Sclerostin binds to the low density receptor, lipo-
protein receptor-related protein 5 (LRP5), and promotes Wnt-
blocking by releasing intra-cellularβ-catenin to the cytoplasm
that ultimately leads to osteoblast differentiation (3). In pa-
tients with RA, sclerostin may be responsible for the low level
of bone repair, and inhibition of the protein could effectively
increase repair of bone erosions in experimental arthritis (10).
Joint destruction as a measurement of the severity of RA is
evaluated by the extent of radiologically detected progression
of joint damage. It is important to identify those patients with
rapidly progressive joint destruction in order to initiate a more
aggressive treatment regimen (11). Useful biomarkers for the
severity of disease progression are currently sparse in patients
with RA; as a consequence, patient treatment is rarely individ-
ualized. Currently used models in clinical practice to predict
the destructive disease course involve degradation products of
cartilage or bone, rheumatoid factor (RF), anti-citrullinated
protein antibodies (ACPA), and/or measurements of inflam-
matory activity [e.g., DAS28, C-reactive protein, erythrocyte
sedimentation rate (ESR)] (11–13). However, there is a need
for more biomarkers to increase the reliability of analyses to
predict the disease progression.
In this study of radiological findings at baseline and after
24 months in patients with early RA, we have evaluated base-
line values of RANKL and sclerostin as potential biomarkers
for assessing a more aggressive disease course. We also aimed
to investigate the relationships between gene polymorphisms
of the two proteins, sclerostin and RANKL, extracted from the




A total of 407 patients (69% female) with early RA (i.e., the
duration of symptoms <1 year) (14) who underwent radiolog-
ical examination at inclusion and after 24 months were con-
secutively included in the study. These patients belong to a
prospective inception cohort study, but for this study, only
individuals with radiological examinations at baseline and
consistently performed after 24 months were included.
Disease activity score (DAS28) was calculated at baseline
and after 6, 12, 18, and 24 months using the 28-joint count
of tender (TJC) and swollen joints (SJC), the patient’s global
assessment, and erythrocyte sedimentation rate (ESR, mm/h)
(15). The concentrations of ESR, C-reactive protein (CRP,
mg/L), and of RF as Waaler-Rose hemagglutination test with
sensitized sheep red blood cells for RF were analyzed accord-
ing to routine clinical protocols. Sensitivity analyses of base-
line data between the whole inception cohort and the cohort
with x-ray data as included in this study did not show any
significant differences between the groups concerning
DAS28, CRP, ESR, SJC, and TJC or the treatments. The pa-
tients were treated during the 24 months with the aim of
achieving remission by using disease-modifying anti-rheu-
matic drugs (DMARDs) or corticosteroids with respect to
the clinical situation identified by the patients’ physician.
During the first 24 months (mean ± SEM duration,
9.8 ± 0.5 months), 52.3% were treated with corticosteroids
(mean dose ± SEM, 6.9 ± 0.2 mg/day), 98.3% with
DMARDs [in 88.1% methotrexate (mean ± SEM duration,
20.4 ± 0.4 months; mean dose ± SEM, 18.2 ± 1.9 mg/week
orally or injectable), 39.1% sulfasalazine (dose 1000–
2000 mg/day), 28.7% chloroquine (dose 200–400 mg/day),
9.1% myocrisine (10–50 mg/week), 5.2% azathioprine (50–
150 mg/day), 2.2% cyclosporin (100–175 mg/day), 2.0%
leflunomide (10–20 mg/day), and as combination therapy in
36.8%], and 9.1% with biologics (adalimumab, etanercept,
infliximab). Response to treatment was evaluated at 6 and
24 months using EULAR response criteria (16).
Blood samples were collected from patients at baseline,
i.e., when presenting with early RA. As controls, a total of
71 (81.7% female) individuals were collected from the
Medical Biobank of Northern Sweden and matched, from
the same geographical area as the patients, for sex and range
of age at a group level. Patients and controls were classified
either as being a Bnon-smoker^ or an Bever-smoker^ (past or
current). Anti-cyclic citrullinated peptide antibodies (anti-
CCP2 antibodies) were detected using enzyme-linked immu-
nosorbent assay according to the manufacturer’s instructions
(Euro-Diagnostica AB, Malmö, Sweden) with a cut-off value
for positivity at 25 AU/mL. Genotyping of HLA-DRB1 was
performed as previously described and HLA-SE was defined
asHLA-DRB1*0401/0404/0405/0408/0101 as previously de-
scribed (19)
Descriptive data of the patients with early RA at inclusion
and controls are presented in Table 1. The participants gave
their written informed consent, and the Regional Ethics
Committee at the University Hospital in Umeå approved the
study.
Evaluation of radiographs
Radiographs of the hands, wrists, and feet at baseline and after
2 years were graded according to the Larsen score by two
specially trained rheumatologists (17). Radiological progres-
sion was defined as the increase of the Larsen score between
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baseline and 24 months, with the smallest detectable change
of less than 4 calculated according to Bruynesteyn et al. (18).
Immunoassays for sclerostin and RANKL
Human Sclerostin HS EIA Kit (TECOmedical Group,
Sissach, Switzerland) was used to measure concentrations of
sclerostin in plasma from patients and controls according to
the manufacturer’s instructions. The range of detection was
0.165 to 2.578 ng/mL. The cut-off for sclerostin positivity
was set as the 95th percentile of the controls, i.e., 1.14 ng/
mL. Human RANKL ELISA (BioVendor, Karasek,
Czech Republic) was used to determine the total RANKL
concentrations (free and bound) in plasma performed accord-
ing to the manufacturer’s instructions. The range of detection
was 0.05 to 3.20 nmol/L. The cut-off for positivity of RANKL
was set as the 95th percentile, i.e., 0.92 nmol/L.
Gene polymorphism
Data on gene polymorphisms were extracted from
Immunochip analysis (SNP&SEQ Technology Platform,
Uppsala, Sweden) covering three single nucleotide polymor-
phisms (SNPs) for SOST gene and 539 for the TNFSF11 gene
(20). Information about the protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) C1858T was also extracted from
the Immunochip analysis.
Statistical analysis
For comparative analyses between continuous data, non-
parametrical tests were used since the variables were not nor-
mally distributed. The Mann-WhitneyU test was used for two
groups and the Kruskal-Wallis test for more than two groups.
Univariate analyses of variance were used to investigate the
relative strengths of the relationships between the variables
(presented in Tables 3 and 4) and radiographic outcome.
Thereafter, all significant variables were included in multivar-
iate analyses. Radiological progression was analyzed and di-
chotomized in relation to the SNPs. Area under the curve
(AUC) was calculated for DAS28, CRP, and ESR during 6,
12, and 24 months. The concentration of RANKL was trans-
formed to log10 as it was not normally distributed. Additive
interactions were calculated as the attributable proportion (AP),
the relative excess risk due to interaction (RERI) and the syn-
ergy index (SI) with confidence intervals (CI). Multiplicative
interaction (MI) was assessed by adding an interaction variable
to logistic regression models. Calculations were performed
using IBM SPSS Statistics (version 21.0) for Windows and
statistical significance was considered as p ≤0.05. Genetic anal-
yses of SNPs in relation to concentration were performed using
PLINK (1.07) (21) andHaploview (4.2) for the permutation test
(http://www.broad.mit.edu/mpg/haploview).
Results
The concentration of RANKL analyzed in samples collected
at baseline was significantly increased in patients compared
with controls, median (quartile 1–quartile 3) 0.56 (0.26–
1.16) nmol/L and 0.20 (0.13–0.38) nmol/L, respectively
(p < 0.001) (Fig. 1a). Anti-CCP-positive patients had signifi-
cantly higher concentration of RANKL compared with anti-
CCP-negative patients, median (Q1–Q3) 0.764 (0.347–
1.325) nmol/L and 0.242 (0.138–0.474) nmol/L as was the
concentration in RF-positive patients (Fig. 1b). A significantly
increased concentration in anti-CCP-positive patients
remained when analyzed in individuals sero-negative for RF
(p < 0.02). The concentration of RANKL was related to ESR
at baseline and at 12months adjusted for age and sex (p < 0.01
for both) and correlated with AUC-ESR6, 12 and 24 months,
respectively (correlation coefficient 0.12–0.13, p < 0.05 for all
three), but was unrelated to DAS28, CRP, TJC, or SJC, sex,
age, and smoking habits. The frequency of RANKL above
cut-off (defined as above the 95th percentile of the controls’
values) was 32.9%. The presence of positivity for RANKL
was significantly associated with positivity for anti-CCP2 an-
tibodies and RF (p < 0.001) and with AUC-ESR6, 12 and
24 months (p < 0.05 for all three).
Table 1 Descriptive data for 407
patients with early rheumatoid
arthritis and for 71 controls, at the
time of inclusion into the study
and during follow-up until
24 months
Variables RA patients (N = 407) Controls (N = 71)
Age (mean) ± SD, years 53.8 ± 14.5 54.9 ± 14.5
Female, n (%) 281/407 (69) 58/71 (81.7)
HLA-SE, n (%) 242/404 (59.9)* 30/67 (44.8)
PTPN22 1858T carriage (%) 137/402 (34.1) 18/52 (25.7)
RF+, n (%) 327/407 (80.3) –
Anti-CCP2 abs+, n (%) 305/407 (74.9)*** 1/71 (1.4)
HLA-SE HLA shared epitope = 0101/0401/0404/0405/0408, RF rheumatoid factor, Anti-CCP2 abs anti-CCP2
antibodies
* p < 0.05, ***p < 0.001
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Analyses of the combinations of RANKL and anti-CCP2
(presented in Table 2) showed an increase of OR for radiolog-
ical progression when being positive for both compared with
being negative for both as reference. However, interaction anal-
ysis, additive or multiplicative, did not show a significant inter-
action between these factors (Table 2). The combinations of
being both RANKL and anti-CCP2 positive yielded also sig-
nificantly higher Larsen score at 24 months (data not shown).
The concentration of sclerostin was also significantly in-
creased in RA patients, median (Q1–Q3) 0.63 (0.49–0.78) ng/
mL versus controls 0.51 (0.4–0.7) ng/mL (p < 0.01) (Figs. 1c
and 2). However, when stratified for sex, the levels were only
significantly increased in female patients, 0.59 (0.47–0.74) ng/
mL, compared with 0.49 (0.4–0.65) ng/mL in female controls
(p < 0.02). The concentration of sclerostin was affected by age
with increasing concentration in both sexes [β = 0.008 (95%CI
0.004, 0.012), p < 0.001 for males and β = 0.005 (95% CI
0.003, 0.007), p < 0.001 for females]. There were no relation-
ships between sclerostin concentrations and anti-CCP2 antibod-
ies or any makers of inflammation (e.g., DAS28, ESR, CRP, or
joint count calculated separately or for AUC values).
Carrier of HLA-SE and the PTPN22 T-variant were not
related to the concentrations of RANKL or sclerostin. During
the 24 months of the study, the DAS28 decreased significantly
in the patients (p < 0.001) (Supplementary Table 1) while the
Larsen score increased significantly (p < 0.001) during the cor-
responding time. At 6 months, 60.3% were good-moderate re-
sponders, and at 24 months, 72.5% were responders.
Predictors of radiographic outcome: univariate analysis
of variance
The concentration of RANKL and RANKL positivity, but not
the log RANKL, was related to the Larsen score at inclusion
as were carriage of PTPN22 T variant and greater age at
Fig. 1 a Concentration of RANKL in patients and control subjects. b
Concentration of RANKL in patients stratified for anti-CCP2 antibodies
Table 2 Odds ratio (OR, 95%
CI) for combinations of RANKL
(positive/negative) and anti-
CCP2 antibodies for radiological
progression at 24 months
RANKL Anti-CCP2 Radiological progression yes/no OR (95% CI)
− − 27/59 1.0 (ref.)
+ − 4/11 0.80 (0.23, 2.72)
− + 81/97 1.83 (1.06, 3.14)
+ + 60/56 2.34 (1.31, 4.20)
RERI = 0.7219148 ( −1.548815, 2.185976)
AP = 0.3083433 (−0.08292323, 0.6392927)
SI = 2.165591 (0.2539086, 18.47037)
MI = 1.614709 (0.4322704, 6.032153), p value = 0.476067
Fig. 2 Concentration of sclerostin in patients and control subjects
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inclusion and baseline values for DAS28, ESR, and SJC
(Table 3). RANKL, measured as concentration or positivity,
were related to the Larsen score at 24 months, as were age, male
sex, Larsen score at baseline and the presence of RF and anti-
CCP antibodies, and inflammatory activity measurements at all
time points as measured by CRP (p value <0.001–0.01), ESR (p
value <0.001 at all time points), SJC (p value 0.001–0.05),
DAS28 (p value 0.001–0.05, respectively, except for non-
significant at 24 months), and response to therapy at 24 months.
The concentration of RANKL, as both crude or log value,
was also related to radiographic progression at 24 months as
well as male sex, baseline values for Larsen score, RF and anti-
CCP2 antibodies, and inflammatory markers from all time
points except for baseline values of CRP and ESR but for re-
sponse to therapy at both 6 and 24 months. Carriage of HLA-
SE was not related to the radiological findings (Table 3). The
levels of sclerostin were unrelated to the radiological findings.
Multiple regression analyses of variance
Including the variables significantly related to the radio-
logical findings in univariate analyses of variance for a
multiple analyses of variance showed that only age
remained significantly associated with Larsen score at
baseline (Table 4). The Larsen score at 24 months was
related to the RANKL concentration adjusted for Larsen
score at baseline, anti-CCP2 antibodies, sex, DAS28, and
response at 24 months. The radiological progression was
related to the log RANKL concentration with the same
adjustments (Larsen score at baseline, DAS28, anti-
CCP2 antibodies, sex, and therapeutic response both at 6
and 24 months) in the multiple analyses of variance
(Table 4). In all of the analyses, similar results were
achieved when including RANKL concentration as crude
value [β value (95% CI) for Larsen score at inclusion,
0.84 (0.23–1.46), p = 0.007; Larsen score at 24 months,
0.67 (0.15–1.19), p = 0.012; and radiological progression,
0.75 (0.21–1.28), p < 0.006]. C-reactive protein or ESR
instead of DAS28 from the different time points at which
they were collected yielded similar results as DAS28
values (data not shown). Adjustment for corticosteroid
and/or DMARDs treatment (yes/no) or duration of treat-
ment did not affect the results (data not shown).
The associations of SNPs of TNFSF11 and SOST, extracted
from the Immunochip, respectively were determined by linear
regression analysis using PLINK. Of the TNFSF11 gene, 50
Table 3 Univariate analyses of variance of clinical and laboratory data as potential predictors for joint destruction in patients with early RAmeasured
at baseline and after 24 months
Larsen score (inclusion) Larsen score (24 months) Radiographic progress (24 months)
β value (95% CI) p value β value (95% CI) p value β value (95% CI) p value
Age at onset 0.13 (0.10–0.17) <0.001 0.13 (0.07–0.19) <0.001 ns
Sex ns 2.02 (0.22–3.82) 0.028 1.74 (0.62–2.85) 0.002
Larsen score at baseline – 1.11 (1.02–1.19) <0.001 0.15 (0.06–0.23) 0.001
Erosions at baseline – 6.9 (5.27–8.55) <0.001 ns
PTPN22 1858T 1.40 (0.12–2.68) 0.033 ns ns
RF positivity ns 3.05 (0.95–5.14) 0.004 2.14 (0.84–3.44) 0.001
Anti-CCP positivity ns 2.68 (0.76–4.6) 0.006 1.72 (0.52–2.92) 0.005
RF/anti-CCP positivity ns 3.46 (1.37–4.96) 0.001 1.94 (0.82–3.06) 0.001
RANKL concentration (nmol/L) 0.91 (0.29–1.53) 0.004 1.8 (0.98–2.67) <0.001 0.99 (0.45–1.52) <0.001
RANKL positivitya 1.26 (0.02–2.54) 0.053 2.58 (0.82–4.33) 0.004 1.32 (0.22–2.42) 0.019
Log RANKL, concentration (nmol/L) 0.76 (−0.5–2.02) 0.234 2.38 (0.65–4.10) 0.007 0.112 (0.01–0.21) 0.032
Sclerostin concentration (ng/mL) 0.93 (−1.64–3.50) 0.477 −0.19 (−3.74–3.37) 0.92 −0.92 (−3.13 to 1.29) 0.411
Sclerostin positivitya 0.89 (−2.85–4.64) 0.639 −1.50 (−6.66–3.66) 0.567 −2.21 (−5.42 to 0.99) 0.176
CRP baseline ns 0.05 (0.02–0.10) 0.004 0.03 (0.01–0.06) 0.007
ESR baseline 0.03 (0.00–0.06) 0.05 0.06 (0.02–0.10) 0.002 0.04 (0.01–0.06) 0.002
SJC baseline 0.24 (0.12–0.35) <0.001 0.30 (0.14–0.46) <0.001 ns
DAS28, baseline 0.59 (0.15–1.02) 0.008 0.7 (0.10–1.29) 0.022 ns
Response at 6 months ns ns −1.38 (−0.31 to 2.45) 0.012
Response at 24 months ns −2.13 (−0.15 to 3.99) 0.024 −1.68 (−0.51 to 2.85) 0.005
CI confidence interval, ESR erythrocyte sedimentation rate, DAS28 disease activity score, CRP C-reactive protein, anti-CCP anti-cyclic citrullinated
peptide, RF rheumatoid factor, TJC tender joint count, SJC swollen joint count
a Cut-off for RANKL and sclerostin was based on above the 95th percentile of the controls
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SNPs were associated with the concentration of RANKL
(p < 0.003–0.05, uncorrected). All SNPs from the
Immunochip were located upstream of the coding region of
the gene. After permutation test as a correction for multiple
testing, no association between any of the SNPs and the con-
centration remained significant. Radiological progression was
associated with 10 of the same SNPs as the concentration and,
furthermore, 14 other SNPs within the same area as those for
concentration. However, none of them remained significant
after correction for multiple testing. The levels of sclerostin
were not related to any of the three available SNPs from the
Immunochip data (rs3785806, rs2090019, rs1513670).
Discussion
In this study, we have shown that there is a clear relationship
between RANKL and the Larsen score at baseline and at
24 months and radiological progression at 24 months before
and after adjustments for markers of disease activity.
Consequently, RANKL concentration can give prognostic in-
formation of joint destruction already at baseline predicting
the outcome after the first 2 years of disease progression. In
a previous study, the ratio of RANKL/osteoprotegerin was
shown to be a predictive marker of radiological progression
over 11 years as opposed to RANKL alone (22). We can,
therefore, in contrast to that study performed on several bio-
markers, identify RANKL as a valuable predictor for radio-
graphically detected progression (23). In that study, only free
RANKLwas detected, while in our study both free and bound
RANKL was measured. However, that study was performed
over a longer time course, 5 and 10 years, and identified C-
telopeptide-1 as a marker (23). RANKL has been concluded
as a good biomarker for structural damage of average strength
of evidence (24), although further studies on larger cohorts
have been suggested.
The concentration of RANKLwas particularly increased in
anti-CCP2- or RF-positive patients. The concentration of
RANKL remained significantly increased in anti-CCP2-
positive patients who were RF negative, a finding in line with
results reported by others (25). A particularly strong radiolog-
ical progression was found in patients with the combination of
RANKL and anti-CCP2 antibodies. Despite the two factors
being significantly related, we were unable to show any inter-
action between these two factors. The association between
ACPA, with or without RF, and radiological progression has
been shown in several studies (12, 26, 27). In a previous study
on individuals before the onset of symptoms, we found an
association between presence of anti-CCP2 antibodies and
radiological findings, as measured by the Larsen score at the
time of diagnosis of RA years later (27). Also, an increased
magnitude of ACPA isotypes has been associated with more
radiological damage (28). Both ACPA and RANKL have
been shown to affect osteoclasts by promoting osteoclast dif-
ferentiation (29). Their potential mechanisms of interactions
have not been demonstrated although we found a statistical
association between the two factors without being able to
show a statistical interaction of the two factors. RANKL con-
centration has been shown to be up-regulated by pro-
inflammatory cytokines and is suggested to be of importance
for inflammatory bone loss in patients with RA (5). Our find-
ings of relationships between the levels of RANKL and ESR,
both on a group and individual level, support a relationship
with inflammation. However, there were no significant rela-
tionships between CRP or DAS28 and RANKL levels on
different time points or as accumulated values (AUC). We
were unable to evaluate the potential effects of treatment since
almost all patients were on DMARD therapy. Corticosteroid
treatment included in the models did not affect the results.
Despite the fact that there was an increased concentration
of sclerostin in female patients comparedwith controls, we did
not find a significant relationship between the concentrations
Table 4 Multivariate analyses of variance including factors of potential predictors for joint destruction in patients with early RAmeasured at baseline
and 2 years
Larsen score at inclusiona Larsen score at 24 months Radiological progression at 24 months
β value (95% CI) p value β value (95% CI) p value β value (95% CI) p value
Age at onset, years 0.108 (0.066–0.149) <0.001 – –
Sex – 2.10 (1.03–3.17) <0.001 2.05 (0.96–3.14) <0.001
Larsen, baseline – 1.09 (1.00–1.17) <0.001 0.13 (0.05–0.21) 0.002
Anti-CCP positivity ns 1.35 (0.15–2.54) 0.028 1.37 (0.15–2.58) 0.027
Log RANKL concentration (nmol/mL) 0.52 (−0.79 to 1.84) 0.43 1.11 (0.03–2.19) 0.045 1.20 (0.10–2.30) 0.033
DAS28 baseline 0.38 (−0.04 to 0.80) 0.075 0.36 (−0.01 to 0.72) 0.056 0.48 (0.09–0.86) 0.016
Response at 6 months – – −1.29 (−0.24 to 2.33) 0.016
Response at 24 months – −2.35 (−1.23 to 3.47) <0.001 −2.1 (−0.94 to 3.24) <0.001
aAdjustment: PTPN22 T variant. CI confidence interval, DAS28 disease activity score, anti-CCP anti-cyclic citrullinated peptide
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or positivity for sclerostin and radiological findings. This was
in line with two other recently published studies on radiolog-
ical findings in RA (30, 31). However, the number of
sclerostin-positive patients in this study was low, 18 (4.4%),
reducing the strength of the calculated results. Sclerostin
levels are related to bone mineral density, which could possi-
bly explain our findings (32). We do not know the bone min-
eral density of our patients included in this study, but as most
of them are postmenopausal with RA, we can assume they
will have decreased bone density compared to the controls,
e.g., women from the general population.
We have also investigated the gene polymorphisms of
the sclerostin (SOST) and RANKL genes (TNFSF11) in
relation to concentrations of sclerostin, RANKL, and to
radiological progression. Polymorphisms of 50 of the
SNPs for the RANKL gene showed increased concentra-
tions of RANKL and for some of them with radiological
findings, although no SNP remained significantly related
to the concentration or radiological findings after
correcting for multiple testing. In a small study from
Japan, one SNP (rs2277438) in RANKL gene was associ-
ated with radiographic progression at 2 years (33). We
were unable to evaluate this SNP in our study as it was
not included in the Immunochip. Risk alleles of genetic
variants of DKK-1 in patients with RA have previously
been associated with a more progressive course of joint
destruction over time and higher concentrations in serum
of functional Dickkopf-1 (34). We could not find a similar
relationship for sclerostin even though it is involved in the
same pathway as Dickkopf-1. Three SNPs for sclerostin
(rs3785806, rs2090019, rs1513670) were not associated
to either concentration of sclerostin in plasma or to radio-
logical progression. However, previous studies have
shown that several variants in DKK-1 and other SOSTwere
related to structural damage and progression, but we were
not able to confirm that findings in our study (35).
In summary, we have shown that measurement of
RANKL concentration, on its own, can be a valuable pre-
dictor for Larsen score at 24 months and long-term radio-
logical progression irrespective of disease activity. The
combination of RANKL and presence of anti-CCP2 anti-
bodies are markers for a more destructive process. The
presence of these markers suggests initiation of a more
aggressive treatment regimen. Furthermore, we were un-
able to show that the polymorphisms of the RANKL
SNPs were associated with the concentration of RANKL
or with the radiological progression. Sclerostin was not
related to the radiological findings during the first
24 months.
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